In an ongoing phase I clinical trial at Sun Yat-sen University, C-X-C chemokine receptor (CXCR) type 5-modified anti-EGFR CAR-T cells are being assessed for efficacy and safety in treating EGFR-positive patients with advanced NSCLC (ClinicalTrials.gov identifier: NCT04153799). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.